전문 번역가, 번역 회사, 웹 페이지 및 자유롭게 사용할 수 있는 번역 저장소 등을 활용합니다.
tumuri u mard limfoproliferattiv
malignancies and lymphoproliferative disorders
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
disturb limfoproliferattiv wara t-trapjant
post transplant lymphoproliferative disorder
마지막 업데이트: 2017-04-26
사용 빈도: 2
품질:
kien irrapportat disturb limfoproliferattiv assoċjat ma 'ebv.
ebv-associated lymphoproliferative disorder has been reported.
마지막 업데이트: 2011-10-23
사용 빈도: 1
품질:
경고: 이 정렬은 잘못되었을 수 있습니다.
잘못된 경우 삭제해 주십시오.
tumuri malinni u mard limfoproliferattiv wara t-trapjant
malignancies and post-transplant lymphoproliferative disease
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
immunosuppressjoni eċċessiva b’ riskju ta ’ mard limfoproliferattiv.
excessive immunosuppression with risk of lymphoproliferative disease.
마지막 업데이트: 2012-04-10
사용 빈도: 2
품질:
disturb limfoproliferattiv ta’ wara t-trapjant (ptld)
post-transplant lymphoproliferative disorder (ptld)
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
mard limfoproliferattiv mill-ebv (virus ta’ epstein-barr)
ebv (epstein-barr virus) lymphoproliferative disease
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
ciclosporin, tacrolimus: immunosuppressjoni eċċessiva b’riskju ta’ mard limfoproliferattiv.
ciclosporin, tacrolimus: excessive immunosuppression with risk of lymphoproliferative disease.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
pazjenti li qed jieħdu tacrolimus dehru li żviluppaw disturbi limfoproliferattiv marbutin ma ’ l- ebv.
patients treated with tacrolimus have been reported to develop ebv-associated lymphoproliferative disorders.
마지막 업데이트: 2012-04-10
사용 빈도: 2
품질:
Ġie rrapportat li t-twaqqif tal-immunosuppressjoni jista' jipprovdi rigressjoni parzjali tad-disturb limfoproliferattiv.
it has been reported that discontinuation of immunosuppression may provide partial regression of the lymphoproliferative disorder.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
pazjenti fuq terapija immunosoppressiva wara trapjant huma f’riskju ikbar li jiżviluppaw mard limfoproliferattiv (lpds) u infezzjonijiet opportunistiċi.
patients on immunosuppressive therapy following transplantation are at increased risk for developing lymphoproliferative disorders (lpds) and opportunistic infections.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
disturbi limfoproliferattivi il-kura b’xaluprine żżidlek ir-riskju li jkollok tip ta’ kanċer li jissejjaħ disturb limfoproliferattiv.
lymphoproliferative disorders treatment with xaluprine increases your risk of getting a type of cancer called lymphoproliferative disorder.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
pazjenti li kellhom trapjant li qed jirċievu kura immunosoppressiva b’ korsijiet flimkien ma ’ basiliximab jew mingħajru għandhom riskju akbar li jiżviluppaw mard limfoproliferattiv (lpds)
in a pooled analysis of two
마지막 업데이트: 2011-10-23
사용 빈도: 1
품질:
경고: 이 정렬은 잘못되었을 수 있습니다.
잘못된 경우 삭제해 주십시오.
marbuta mal-kura b’tacrolimus ġew rapportati neoplażmi beninji kif ukoll malinji li jinkludu disturbi limfoproliferattiv assoċjati ma’ ebv kif ukoll tkabbir malinn fil-ġilda.
benign as well as malignant neoplasms including ebv-associated lymphoproliferative disorders and skin malignancies have been reported in association with tacrolimus treatment.
마지막 업데이트: 2017-04-26
사용 빈도: 3
품질:
fi studju ieħor li fih kienu rreġistrati pazjenti ta ’ ≤20 sena li kellhom trapjant tal- kliewi li kien maħsub biex jevalwa s- sigurtà ta ’ twaqqif progressiv tal- kortikosterojdi (li beda sitt xhur wara t- trapjant) minn kors immunosoppressiv li nbeda mat- trapjant li kien jinkludi immunosoppressjoni b’ doża sħiħa kemm b’ rapamune kif ukoll b’ impeditur ta ’ calcineurin flimkien ma ’ induzzjoni ta ’ basiliximab, mill- 274 pazjent li rreġistraw, 19 (6. 9%) kienu rrappurtati li żviluppaw disturb limfoproliferattiv ta ’ wara t - trapjant (ptld).
in another study enrolling renal transplant patients 20 years of age that was intended to assess the safety of progressive corticosteroid withdrawal (beginning at six months post-transplantation) from an immunosuppressive regimen initiated at transplantation that included full-dose immunosuppression with both rapamune and a calcineurin inhibitor in combination with basiliximab induction, of the 274 patients enrolled, 19 (6.9%) were reported to have developed post-transplant lymphoproliferative disorder (ptld).
마지막 업데이트: 2012-04-10
사용 빈도: 6
품질: